Trials / Completed
CompletedNCT04034134
Study to Evaluate the Safety and Efficacy ofJaktinib Hydrochloride Tablets in Severe Alopecia Areata
A Phase Ⅱ Study to Evaluate the Safety and Efficacy of Jaktinib Hydrochloride Tablets in the Treatment of Severe Alopecia Areata.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 111 (actual)
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This was an open-label, Multi-center, randomized phase Ⅱ study. Patients with severe Alopecia Areata were randomized to receive 50mg bid, 150mg qd or 200 mg qd of oral Jaktinib Hydrochloride Tablets.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Jaktinib Hydrochloride Tablets | 50 mg twice-daily (BID) |
| DRUG | Jaktinib Hydrochloride Tablets | 150 mg quaque die (QD) |
| DRUG | Jaktinib Hydrochloride Tablets | 200 mg quaque die (QD) |
Timeline
- Start date
- 2019-11-18
- Primary completion
- 2021-11-26
- Completion
- 2021-11-26
- First posted
- 2019-07-26
- Last updated
- 2022-11-29
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04034134. Inclusion in this directory is not an endorsement.